PEPITEM Regulates the Synovial Microenvironment During Immune‐Mediated Inflammatory Arthritis to Limit Disease
Authors' conclusion
Collectively, these findings underscore the importance of understanding the dysregulation of the adiponectin-PEPITEM pathway in different immune-mediated inflammatory diseases (IMIDs), such as RA and PsA.
Study context
- Population
- Patients with clinical suspect arthralgia and suspected inflammatory arthritis (early, treatment-naive rheumatoid arthritis (RA) and psoriatic arthritis (PsA)); mice with inflammatory arthritis
- Comparison
- PEPITEM treatment in inflammatory arthritis mouse models; adiponectin-PEPITEM pathway in early, treatment-naive RA and PsA
Methodological detailshuman peripheral blood analysis (flow cytometry, Western blot), preclinical animal models (three distinct inflammatory arthritis models)
- Human peripheral blood analysis (flow cytometry, Western blot)
- Preclinical animal models (three distinct inflammatory arthritis models)
Main finding
As reported in the abstract
- Newly diagnosed RA and PsA: significantly reduced expression of adiponectin receptor 2 and APPL-1 on PBMCs, with diminished response to adiponectin and local synovial PEPITEM concentrations
- PEPITEM in three inflammatory arthritis animal models: significantly reduced arthritis severity, joint swelling, leukocyte infiltration and synovial pro-inflammatory mediators (eg, JE [CCL2], RANTES, IL-16)
- PEPITEM suppressed cyclooxygenase 2 and NF-κB signalling pathways
- PEPITEM altered the composition of leukocyte subsets recruited into the joint
Original publication
PEPITEM Regulates the Synovial Microenvironment During Immune‐Mediated Inflammatory Arthritis to Limit Disease. Arthritis Rheumatol. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →